239 related articles for article (PubMed ID: 17571902)
1. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain.
Raju TS; Scallon B
Biotechnol Prog; 2007; 23(4):964-71. PubMed ID: 17571902
[TBL] [Abstract][Full Text] [Related]
2. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides.
Wormald MR; Rudd PM; Harvey DJ; Chang SC; Scragg IG; Dwek RA
Biochemistry; 1997 Feb; 36(6):1370-80. PubMed ID: 9063885
[TBL] [Abstract][Full Text] [Related]
3. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
4. Site-specific N-glycosylation of chicken serum IgG.
Suzuki N; Lee YC
Glycobiology; 2004 Mar; 14(3):275-92. PubMed ID: 14693911
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.
Raju TS; Scallon BJ
Biochem Biophys Res Commun; 2006 Mar; 341(3):797-803. PubMed ID: 16442075
[TBL] [Abstract][Full Text] [Related]
6. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
[TBL] [Abstract][Full Text] [Related]
7. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.
Jones AJ; Papac DI; Chin EH; Keck R; Baughman SA; Lin YS; Kneer J; Battersby JE
Glycobiology; 2007 May; 17(5):529-40. PubMed ID: 17331977
[TBL] [Abstract][Full Text] [Related]
8. Production and molecular characterization of clinical phase i anti-melanoma mouse IgG3 monoclonal antibody R24.
Kemminer SE; Conradt HS; Nimtz M; Sagi D; Peter-Katalinić J; Diekmann O; Drmić I; Müthing J
Biotechnol Prog; 2001; 17(5):809-21. PubMed ID: 11587568
[TBL] [Abstract][Full Text] [Related]
9. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
10. Global and site-specific detection of human integrin alpha 5 beta 1 glycosylation using tandem mass spectrometry and the StrOligo algorithm.
Ethier M; Krokhin O; Ens W; Standing KG; Wilkins JA; Perreault H
Rapid Commun Mass Spectrom; 2005; 19(5):721-7. PubMed ID: 15702487
[TBL] [Abstract][Full Text] [Related]
11. Altered O-glycosylation and sulfation of airway mucins associated with cystic fibrosis.
Xia B; Royall JA; Damera G; Sachdev GP; Cummings RD
Glycobiology; 2005 Aug; 15(8):747-75. PubMed ID: 15994837
[TBL] [Abstract][Full Text] [Related]
12. N-glycans of recombinant human acid alpha-glucosidase expressed in the milk of transgenic rabbits.
Jongen SP; Gerwig GJ; Leeflang BR; Koles K; Mannesse ML; van Berkel PH; Pieper FR; Kroos MA; Reuser AJ; Zhou Q; Jin X; Zhang K; Edmunds T; Kamerling JP
Glycobiology; 2007 Jun; 17(6):600-19. PubMed ID: 17293352
[TBL] [Abstract][Full Text] [Related]
13. Site-specific N-glycan characterization of human complement factor H.
Fenaille F; Le Mignon M; Groseil C; Ramon C; Riandé S; Siret L; Bihoreau N
Glycobiology; 2007 Sep; 17(9):932-44. PubMed ID: 17591618
[TBL] [Abstract][Full Text] [Related]
14. Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.
Antes B; Amon S; Rizzi A; Wiederkum S; Kainer M; Szolar O; Fido M; Kircheis R; Nechansky A
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):250-6. PubMed ID: 17296336
[TBL] [Abstract][Full Text] [Related]
15. N-glycan structures and N-glycosylation sites of mouse soluble intercellular adhesion molecule-1 revealed by MALDI-TOF and FTICR mass spectrometry.
Otto VI; Damoc E; Cueni LN; Schürpf T; Frei R; Ali S; Callewaert N; Moise A; Leary JA; Folkers G; Przybylski M
Glycobiology; 2006 Nov; 16(11):1033-44. PubMed ID: 16877748
[TBL] [Abstract][Full Text] [Related]
16. A two-dimensional array for simultaneous sequencing of N- and o-glycans and their glycoforms on specific glycosylation sites.
Tzur Y; Markovich A; Lichtenstein RG
J Proteome Res; 2008 Mar; 7(3):1188-98. PubMed ID: 18205330
[TBL] [Abstract][Full Text] [Related]
17. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization.
Huang L; Biolsi S; Bales KR; Kuchibhotla U
Anal Biochem; 2006 Feb; 349(2):197-207. PubMed ID: 16360109
[TBL] [Abstract][Full Text] [Related]
18. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
19. The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.
Leung SO; Qu Z; Hansen HJ; Shih LB; Wang J; Losman MJ; Goldenberg DM; Sharkey RM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3106s-3117s. PubMed ID: 10541351
[TBL] [Abstract][Full Text] [Related]
20. Glycosylation pattern of humanized IgG-like bispecific antibody produced by recombinant CHO cells.
Kim WD; Tokunaga M; Ozaki H; Ishibashi T; Honda K; Kajiura H; Fujiyama K; Asano R; Kumagai I; Omasa T; Ohtake H
Appl Microbiol Biotechnol; 2010 Jan; 85(3):535-42. PubMed ID: 19652963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
